Merck
CN
  • Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine.

Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine.

Lipids in health and disease (2012-06-15)
Rahul Nair, Ashok C K Kumar, Vishnu K Priya, Chakrapani M Yadav, Prasanna Y Raju
摘要

The present work aims at preparing aqueous suspension of Solid lipid Nanoparticles containing Chitosan (CT) which is a biopolymer that exhibits a number of interesting properties which include controlled drug delivery. Carbamezapine (CBZ) is a lipophilic drug which shows it antiepileptic activity by inactivating sodium channels. The solid lipid Nanoparticles (SLN) of Chitosan-CBZ were prepared by using solvent injection method using ethanol as organic solvent. The prepared SLN formulations exhibited high encapsulation efficiency, high physical stability. The drug incorporated SLNs have demonstrated that the controlled release patterns of the drug for prolonged period. The prepared SLNs were characterized for surface morphology by SEM analysis, entrapment efficiency, zeta potential, FTIR, DSC and In-vitro diffusion studies. The hydrodynamic mean diameter and zeta potential were 168.7 ± 1.8 nm and -28.9 ± 2.0 mV for SLN-chitosan-CBZ respectively. Therefore chitosan-SLN can be good candidates to encapsulate CBZ and to increase its therapeutic efficacy in the treatment of Epilepsy.

材料
货号
品牌
产品描述

Sigma-Aldrich
三硬脂酸甘油酯, ≥99%
三硬脂精, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
三硬脂酸甘油酯, technical